73 results on '"de Jong, Marion"'
Search Results
2. Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity
3. Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T
4. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
5. Correction to: Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma
6. Necrosis binding of Ac-Lys0(IRDye800CW)-Tyr3-octreotate: a consequence from cyanine-labeling of small molecules
7. Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma
8. Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification
9. To go where no one has gone before: the necessity of radiobiology studies for exploration beyond the limits of the “Holy Gray” in radionuclide therapy
10. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
11. In Vivo Evaluation of Indium-111–Labeled 800CW as a Necrosis-Avid Contrast Agent
12. Imaging of inflammatory cellular protagonists in human atherosclerosis: a dual-isotope SPECT approach
13. Cellular dosimetry of [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
14. Imaging inflammation in atherosclerotic plaques, targeting SST2 with [111In]In-DOTA-JR11
15. Call to arms: need for radiobiology in molecular radionuclide therapy
16. Translational molecular imaging in exocrine pancreatic cancer
17. In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer
18. Generation of fluorescently labeled tracers – which features influence the translational potential?
19. Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?
20. The new era of cancer immunotherapy: what can molecular imaging do to help?
21. Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine
22. Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
23. Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11—first estimates for clinical translation
24. Radiolabeling polymeric micelles for in vivo evaluation: a novel, fast, and facile method
25. Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate
26. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT
27. Triamcinolone acetonide activates an anti-inflammatory and folate receptor–positive macrophage that prevents osteophytosis in vivo
28. Frank Rösch: Nuclear and Radiochemistry, Volume 1: Introduction
29. Highlights lecture EANM 2014: “Gimme gimme gimme those nuclear Super Troupers”
30. Biomarkers in preclinical cancer imaging
31. Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount
32. Imaging preclinical tumour models: improving translational power
33. Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model
34. The role of preclinical SPECT in oncological and neurological research in combination with either CT or MRI
35. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
36. Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin
37. Increased physical activity severely induces osteoarthritic changes in knee joints with papain induced sulfate-glycosaminoglycan depleted cartilage
38. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study
39. PL - 92. Non-invasive determination of the beta cell mass in rats by SPECT with In-111-DTPA-Exendin-3
40. Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607
41. Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptides
42. Preclinical animal research on therapy dosimetry with dual isotopes
43. Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice
44. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues
45. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
46. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides
47. Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours
48. Peptide-receptor radionuclide therapy for endocrine tumors
49. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma
50. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.